Merck & Company Inc (MRK)vsArcus Biosciences Inc (RCUS)
MRK
Merck & Company Inc
$141.16
-0.63%
HEALTHCARE · Cap: $360.08B
RCUS
Arcus Biosciences Inc
$18.39
+1.38%
HEALTHCARE · Cap: $2.82B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 56797% more annual revenue ($66.57B vs $117.00M). MRK leads profitability with a 4.8% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 36/100 (F).
MRK
Hold36
out of 100
Grade: F
RCUS
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$83.64
Current Price
$141.16
$57.52 premium
Margin of Safety
+72.3%
Fair Value
$77.07
Current Price
$18.39
$58.68 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Conservative balance sheet, low leverage
Areas to Watch
Trading at 8.3x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
ROE of -70.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : RCUS
The strongest argument for RCUS centers on Debt/Equity.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 115.8x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : RCUS
The primary concerns for RCUS are EPS Growth, Profit Margin, Piotroski F-Score.
Key Dynamics to Monitor
RCUS carries more volatility with a beta of 0.94 — expect wider price swings.
MRK is growing revenue faster at 5.1% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (36/100 vs 22/100). RCUS offers better value entry with a 72.3% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Arcus Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies in the United States. The company is headquartered in Hayward, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?